{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T19:14:03Z","timestamp":1785438843479,"version":"3.56.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.cllc.2025.01.014","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T19:00:24Z","timestamp":1738695624000},"page":"288-298.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (\u226550%) Patients"],"prefix":"10.1016","volume":"26","author":[{"given":"Adriana P.C.","family":"Barrichello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arielle","family":"Elkrief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0651-2678","authenticated-orcid":false,"given":"Biagio","family":"Ricciuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teja","family":"Ganta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas U.","family":"Marron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Lotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Santo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Cortellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijaya","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Felt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Pfaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lamberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Pecci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro Di","family":"Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maisam","family":"Makarem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malini M.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Haradon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor R.","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Debnath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G.","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwaar","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maluki","family":"Radford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Lovly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline A.","family":"Nebhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Pinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Rodig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Schoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M.","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao V.","family":"Alessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Rafeh","family":"Naqash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2025.01.014_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102394","article-title":"The use of immunotherapy in older patients with advanced non-small cell lung cancer","volume":"106","author":"Tagliamento","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.cllc.2025.01.014_bib0002","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jtho.2018.11.011","article-title":"Impact of age on outcomes with immunotherapy in patients with non\u2013Small cell lung cancer","volume":"14","author":"Lichtenstein","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"12","key":"10.1016\/j.cllc.2025.01.014_bib0003","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1001\/jamaoncol.2021.4960","article-title":"Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer","volume":"7","author":"Nebhan","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cllc.2025.01.014_bib0004","doi-asserted-by":"crossref","unstructured":"Nosaki K, Saka H, Hosomi Y, et al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1\u2013positive advanced non\u2013small-cell lung cancer: pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer. 2019;135:188\u201395. doi: 10.1016\/j.lungcan.2019.07.004.","DOI":"10.1016\/j.lungcan.2019.07.004"},{"issue":"2","key":"10.1016\/j.cllc.2025.01.014_bib0005","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41568-019-0222-9","article-title":"How the ageing microenvironment influences tumour progression","volume":"20","author":"Fane","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.cllc.2025.01.014_bib0006","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40425-015-0091-z","article-title":"Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma","volume":"3","author":"Feng","year":"2015","journal-title":"J Immunother Cancer"},{"issue":"22","key":"10.1016\/j.cllc.2025.01.014_bib0007","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1158\/1078-0432.CCR-12-0397","article-title":"Quantitative immunofluorescence reveals the signature of active B-cell receptor signaling in diffuse large B-cell lymphoma","volume":"18","author":"Bogusz","year":"2012","journal-title":"Clin Ca Res"},{"key":"10.1016\/j.cllc.2025.01.014_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.668340","article-title":"Methods to determine and analyze the cellular spatial distribution extracted from multiplex immunofluorescence data to understand the tumor microenvironment","volume":"8","author":"Parra","year":"2021","journal-title":"Front Mol Biosci"},{"issue":"7511","key":"10.1016\/j.cllc.2025.01.014_bib0009","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.cllc.2025.01.014_bib0010","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41588-023-01355-5","article-title":"Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer","volume":"55","author":"Ravi","year":"2023","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.cllc.2025.01.014_bib0011","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","article-title":"xCell: digitally portraying the tissue cellular heterogeneity landscape","volume":"18","author":"Aran","year":"2017","journal-title":"Genome Biol"},{"issue":"2","key":"10.1016\/j.cllc.2025.01.014_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001007","article-title":"Outcomes to first-line pembrolizumab in patients with PD-L1-high (\u226550%) non\u2013small cell lung cancer and a poor performance status","volume":"8","author":"Alessi","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"10274","key":"10.1016\/j.cllc.2025.01.014_bib0013","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2025.01.014_bib0014","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.3389\/fimmu.2018.03101","article-title":"Immune cell composition in Human non-small cell lung cancer","volume":"9","author":"Stankovic","year":"2019","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.cllc.2025.01.014_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109599","article-title":"Evaluating the impact of age on immune checkpoint therapy biomarkers","volume":"36","author":"Erbe","year":"2021","journal-title":"Cell Rep"},{"issue":"6","key":"10.1016\/j.cllc.2025.01.014_bib0016","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jgo.2022.04.008","article-title":"Geriatric assessment in the management of older patients with cancer \u2013 a systematic review (update)","volume":"13","author":"Hamaker","year":"2022","journal-title":"J Geriatr Oncol"},{"issue":"6","key":"10.1016\/j.cllc.2025.01.014_bib0017","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jtho.2023.01.091","article-title":"Clinicopathologic and genomic factors impacting efficacy of first-line chemoimmunotherapy in advanced NSCLC","volume":"18","author":"Alessi","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"7","key":"10.1016\/j.cllc.2025.01.014_bib0018","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1016\/j.cllc.2023.06.010","article-title":"Pembrolizumab alone or with chemotherapy for 70+ year-old lung cancer patients: a retrospective study","volume":"24","author":"Blasi","year":"2023","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"10.1016\/j.cllc.2025.01.014_bib0019","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.annonc.2021.09.021","article-title":"Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer","volume":"33","author":"Federico","year":"2022","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.cllc.2025.01.014_bib0020","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","article-title":"The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies","volume":"21","author":"Kumagai","year":"2020","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.cllc.2025.01.014_bib0021","doi-asserted-by":"crossref","first-page":"18994","DOI":"10.1038\/s41598-020-76130-1","article-title":"Regulatory (FoxP3+) T cells and TGF-\u03b2 predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer","volume":"10","author":"Koh","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.cllc.2025.01.014_bib0022","doi-asserted-by":"crossref","first-page":"684098","DOI":"10.3389\/fonc.2021.684098","article-title":"Regulatory T-cells as an emerging barrier to immune checkpoint inhibition in lung cancer","volume":"11","author":"Principe","year":"2021","journal-title":"Front Oncol"},{"issue":"14","key":"10.1016\/j.cllc.2025.01.014_bib0023","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1200\/JCO.22.01748","article-title":"Functional engagement of the PD-1\/PD-L1 complex but not PD-L1 expression is highly predictive of patient response to immunotherapy in non\u2013Small-cell lung cancer","volume":"41","author":"S\u00e1nchez-Magraner","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2025.01.014_bib0024","first-page":"127","article-title":"Signal Transduct Target Ther","volume":"6","author":"Duan","year":"2021"},{"issue":"6","key":"10.1016\/j.cllc.2025.01.014_bib0025","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.immuni.2016.12.001","article-title":"The heterogeneity of Ly6Chi monocytes controls their differentiation into iNOS+ macrophages or monocyte-derived dendritic cells","volume":"45","author":"Menezes","year":"2016","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.cllc.2025.01.014_bib0026","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4049\/jimmunol.1701024","article-title":"Dendritic cell\u2013Based cancer vaccines","volume":"200","author":"Santos","year":"2018","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.cllc.2025.01.014_bib0027","article-title":"Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer","volume":"10","author":"Revenko","year":"2022","journal-title":"J Immunother Ca"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425000257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425000257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:47:56Z","timestamp":1762548476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730425000257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1525730425000257"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2025.01.014","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (\u226550%) Patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2025.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}